Want to see IMDX full AI Analyst Report?
Top Page
Insight Molecular Diagnostics
(NASDAQ:IMDX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$4.50
▲(1.35% Upside)
Action:Reiterated
Date:08/11/26
The score is held down primarily by very weak financial performance (losses, negative equity, and substantial cash burn relative to revenue). Technicals are also soft with negative MACD and the stock below key longer-term averages. The main offset is a more positive earnings-call backdrop around FDA progress and reimbursement-driven market expansion, but near-term funding and execution/timing risk remains significant.
Positive Factors
Progress toward FDA authorization
Sustained regulatory progress toward FDA authorization is a durable operational inflection: a kitted approval converts the company from an R&D/regulatory-stage lab into a commercial supplier, materially increasing addressable customers and enabling scale of kit sales and reimbursement capture over multiple years, reducing long-run reliance on small RUO and lab-service revenues.
Negative Factors
Negative stockholders' equity
Cumulative losses that produced negative equity indicate weakened balance‑sheet flexibility and heightened refinancing risk. This structural erosion limits borrowing capacity, increases the probability of dilutive equity raises, and constrains strategic optionality for M&A or investment over the next several quarters unless profitability or funding improves materially.
Read all positive and negative factors
Positive Factors
Negative Factors
Progress toward FDA authorization
Sustained regulatory progress toward FDA authorization is a durable operational inflection: a kitted approval converts the company from an R&D/regulatory-stage lab into a commercial supplier, materially increasing addressable customers and enabling scale of kit sales and reimbursement capture over multiple years, reducing long-run reliance on small RUO and lab-service revenues.
Read all positive factors
Insight Molecular Diagnostics (IMDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$145.30M
Dividend YieldN/A
Average Volume (3M)42.75K
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue Growth-60.77%
EPS Growth57.26%
CountryUS
Employees57
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-1.52
Shares Outstanding32,724,285
10 Day Avg. Volume47,668
30 Day Avg. Volume42,754
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.67Price Target Upside117.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.91
Revenue Forecast (FY)$1.10M
Insight Molecular Diagnostics Business Overview & Revenue Model
Company Description
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States...
How the Company Makes Money
null...
Insight Molecular Diagnostics Earnings Call Summary
Earnings Call Date:Aug 10, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call conveys a generally positive operational and commercial outlook driven by regulatory progress (SIR meeting and tripled study samples), favorable Medicare coverage expansion (+75% surveillance tests in first 3 years), strong head-to-head clinical data and customer engagement (over half of top-10 transplant centers engaged), and a clear TAM expansion pathway. Offsetting these positives are material near-term financial risks — elevated cash burn ($10M in Q2; expected ~$8M/quarter in H2, up ~33% vs prior guidance), ongoing adjusted EBITDA losses ($7.8M) and schedule uncertainty around FDA authorization that could delay commercialization. Overall, management’s tone is constructive and forward-looking, but execution and timing risks remain important near-term considerations.Positive Updates
Progress Toward FDA Authorization
Company expects FDA marketing authorization for GraftAssureDx later this year, has tripled the number of samples collected in the study since March (≈+200% sample increase vs March baseline), received an additional information letter as part of the Class II process, and will hold an SIR meeting to align on the next submission package.
Negative Updates
High Cash Burn and Increased Run-Rate Expectation
Cash burn was $10.0 million in Q2 2026 (described as a high watermark). Management now expects cash burn of approximately $8.0 million per quarter in H2 2026, above a prior expectation of ~$6.0 million per quarter (≈+33% vs prior guidance), driven by timing of regulatory review costs, registry activities, and commercial launch preparations.
Read all updates
Q2-2026 Updates
Positive
Negative
Progress Toward FDA Authorization
Company expects FDA marketing authorization for GraftAssureDx later this year, has tripled the number of samples collected in the study since March (≈+200% sample increase vs March baseline), received an additional information letter as part of the Class II process, and will hold an SIR meeting to align on the next submission package.
Read all positive updates
Company Guidance
The company guided that it still targets FDA marketing authorization “later this year” (subject to agency timing) and will hold an SIR meeting before submitting additional data—since March it has roughly tripled study sample collection; Q2 adjusted EBITDA loss narrowed to $7.8M and cash burn was $10M (the expected high watermark), with an updated cash‑burn outlook of ≈$8M/quarter in H2 (versus a prior ≈$6M/quarter); management expects modest H2 revenue from laboratory services, RUO kit sales (≈$21k in Q2) and GraftAssureCore (reimbursable at $2,753/result), is fully staffed for material revenue growth, sees >50% of top‑10 U.S. transplant centers engaged and ~50% overlap of FDA sites into the registry, models a $2B core TAM based on 2 tests/year (and notes MolDX expanded surveillance from 8→14 tests in the first 3 years post‑kidney transplant will grow TAM), believes it is ~2 years ahead on kitted development versus competitors, and continues to target IVDR/UK self‑certification and commercial readiness in H2.Insight Molecular Diagnostics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.67M | 4.05M | 1.88M | 1.50M | 958.00K | 2.20M |
| Gross Profit | 186.50K | 190.00K | 740.00K | 413.00K | -18.00K | 1.42M |
| EBITDA | -46.82M | -47.92M | -59.02M | -23.12M | -13.31M | -48.46M |
| Net Income | -49.36M | -50.22M | -60.66M | -27.78M | -72.90M | -64.10M |
Balance Sheet | ||||||
| Total Assets | 29.44M | 25.76M | 35.08M | 74.89M | 100.09M | 159.56M |
| Cash, Cash Equivalents and Short-Term Investments | 17.76M | 11.58M | 8.64M | 9.43M | 20.43M | 33.85M |
| Total Debt | 2.63M | 3.50M | 3.66M | 2.87M | 3.54M | 5.68M |
| Total Liabilities | 50.74M | 57.22M | 47.35M | 54.42M | 60.50M | 94.35M |
| Stockholders Equity | -21.30M | -31.46M | -12.27M | 20.47M | 39.59M | 65.22M |
Cash Flow | ||||||
| Free Cash Flow | -30.88M | -25.37M | -21.23M | -23.61M | -49.91M | -38.19M |
| Operating Cash Flow | -26.95M | -22.18M | -20.71M | -23.32M | -45.57M | -35.94M |
| Investing Cash Flow | -3.92M | -3.19M | -512.00K | -932.00K | -4.34M | -13.96M |
| Financing Cash Flow | 23.76M | 28.07M | 20.43M | 12.19M | 35.81M | 78.36M |
Insight Molecular Diagnostics Technical Analysis
Negative
4.44
Price Trends
4.86
Negative
4.87
Negative
5.36
Negative
Market Momentum
-0.16
Negative
43.84
Neutral
80.16
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMDX, the sentiment is Negative. The current price of 4.44 is below the 20-day moving average (MA) of 4.52, below the 50-day MA of 4.86, and below the 200-day MA of 5.36, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 43.84 is Neutral, neither overbought nor oversold. The STOCH value of 80.16 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMDX.
Insight Molecular Diagnostics Risk Analysis
Insight Molecular Diagnostics disclosed 53 risk factors in its most recent earnings report. Insight Molecular Diagnostics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Insight Molecular Diagnostics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $44.73M | 0.77 | 940.81% | ― | -48.76% | -3.02% | |
47 Neutral | $265.63M | -18.36 | -31.27% | ― | 1.32% | 59.94% | |
46 Neutral | $145.30M | -2.83 | 271.76% | ― | -60.77% | 57.26% | |
43 Neutral | $26.74M | -0.61 | -84.91% | ― | ― | -28.83% | |
42 Neutral | $274.56M | -0.58 | 187.62% | ― | -8.79% | -195.46% |
* Healthcare Sector Average
IMDX
Insight Molecular Diagnostics
4.30
1.79
71.31%
ATOS
Atossa Therapeutics
2.65
-8.66
-76.57%
MGNX
MacroGenics
4.04
2.34
137.65%
ELUT
Elutia
1.00
-1.33
-57.08%
SRZN
Surrozen
23.71
12.03
103.00%
TELO
Telomir Pharmaceuticals, Inc.
1.17
-0.31
-20.95%
Insight Molecular Diagnostics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Insight Molecular Nears FDA Authorization for GraftAssureDx Assay
Positive
Aug 10, 2026
In late July 2026, Insight Molecular Diagnostics reported that the FDA had completed a key phase of its substantive review of the GraftAssureDx kitted dd-cfDNA assay and requested additional information, with the company characterizing its interac...
Executive/Board ChangesShareholder Meetings
Insight Molecular Diagnostics Shareholders Back Board and Incentive Plan
Positive
Jun 17, 2026
Insight Molecular Diagnostics held its annual shareholder meeting on June 11, 2026, via live webcast, with 74.19% of voting power represented, and shareholders elected four directors—Joshua Riggs, Andrew Arno, Andrew J. Last and Louis E. Sil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.